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1. ABSTRACT 
 
Angiogenesis is essential in development and 
wound healing and contributes to the pathogenesis of many 
diseases. The signalling pathways activated in angiogenesis 
are, in part ,known and the overall tyrosine phosphorylation  
of cellular proteins plays a relevant role. By RNA 
fingerprinting, we isolated a tyrosine phosphatase, HD-
PTP, modulated in human endothelial cells exposed to 
human immunodeficiency virus type 1 Tat, a viral protein 
known to be angiogenic. For the first time, we describe 
HD-PTP at the protein level. HD-PTP, a 185 kDa cytosolic 
protein which is expressed in endothelial cells of different 
origin. We show that HD-PTP is upregulated by Tat at the 
mRNA but not at the protein level. HD-PTP protein is 
differentially modulated by two angiogenic growth factors. 
While Vascular Endothelial Growth Factor does not affect 
protein levels, Fibroblast Growth Factor-2 induces HD-PTP 
degradation via the proteasome system. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. INTRODUCTION 
 
Angiogenesis is a highly ordered and regulated 
process driving quiescent endothelial cells into a series of 
events culminating with the organization of a vascular 
network that responds to the demands of the growing or 
healing tissues (1). Uncontrolled angiogenesis contributes 
to a number of pathological processes, including 
rheumatoid arthritis, blindness, tumour growth and 
metastasis (2). Angiogenic factors bind to tyrosine kinase 
receptors, triggering the phosphorylation of cytoplasmic 
signalling proteins which modulate endothelial cell 
behaviour, ultimately leading to the formation of new blood 
vessels. The overall protein tyrosine phosphorylation is 
modulated by both tyrosine kinases (PTK) and tyrosine 
phosphatases (PTP). Interestingly, a PTP has been shown to 
strictly regulate Vascular Endothelial Growth Factor 
(VEGF) and Fibroblast Growth Factor (FGF) receptor-
mediated signal transduction and biological activity (3-4).  
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Human HD-PTP, a member of the PTP family, 
has been isolated and located on the short arm of 
chromosome 3 (5), an area frequently deleted in many 
types of human tumours (6,7). It is interesting to note that 
the rat homologue of HD-PTP was reported to inhibit 
activated Ha-ras-mediated NIH-3T3 transformation (8). 
HD-PTP predicted sequence contains a PTP-like domain 
and a PEST motif (rich in proline, glutamine, serine and 
threonine) in the C-terminal region. In the N-terminal 
region, it is homologous to a yeast protein, BRO1, involved 
in the mitogen-activated protein kinase signalling pathway. 
However, HD-PTP protein has not yet been characterized. 
 
In this report we show that HD-PTP is 
differentially expressed in endothelial cells in response to 
HIV-1 Tat (Tat). Apart from enhancing viral transcription, 
Tat also affects the expression of strategic host genes and it 
has angiogenic properties. Indeed, Tat binds the VEGF 
receptor type 2 (VEGF-R2) (9) with consequent transient 
activation of mitogen-activated protein kinase, 
MAPK/ERK(1/2). The interaction with VEGF-R2 is 
required for Tat-induced endothelial growth and migration 
in vitro and for neovascularization in vivo. Tat also 
increases endothelial permeability, an early event in 
angiogenesis, through tyrosine kinases and MAPK 
pathways (10). Interestingly, Tat has a role in the 
pathogenesis of Kaposi’s sarcoma (KS), a highly 
vascularized skin lesion characterized by marked 
endothelial proliferation and migration, resulting in the 
formation of new capillaries (11). Accordingly, Tat transgenic 
mice develop highly vascularized lesions which closely 
resemble KS as well as tumours of different histotypes (12). It 
is noteworthy that a modulation of tyrosine phosphatase 
activity by Tat has been described in several cell types (13,14).  
 
Since Tat modulates endothelial function, we 
assumed that the isolation of differentially expressed genes in 
Tat-treated endothelial cells would yield insights into the 
molecular regulatory mechanisms of early events in the 
angiogenic process. By RNA fingerprinting, we found that Tat 
up-regulates HD-PTP mRNA. In this manuscript, we show for 
the first time that HD-PTP is modulated by Fibroblast 
Growth Factor-2 (FGF-2) through a proteasome dependent 
pathway in endothelial cells. Since Vascular Endothelial 
Growth Factor (VEGF) does not modulate HD-PTP at the 
protein level, we speculate that its regulation requires the 
activation of different intracellular pathways by FGF and 
VEGF.  
 
3. MATERIALS AND METHODS 
 
3.1. Isolation of HD-PTP RNA 
Fingerprinting on 1 µg of total RNA from 
endothelial cells treated with recombinant Tat (Intracel, 
Cambridge, MA) was performed as described (15). The bands 
corresponding to differentially expressed genes were excised 
from the polyacrylamide gel, electroeluted, reamplified by 
PCR, sub-cloned in Bluescript and sequenced. The 2.5 Kb  
fragment of HD-PTP was obtained by screening a human 
umbilical vein endothelial cell (HUVEC) cDNA library 
(Clontech) with the 700-bp fragment obtained by DNA 
fingerprinting. The DNA sequence was analyzed by the 
Analyze and Interpret programs of the Mac Molly Suite 
(Berlin). Deduced protein sequences were compared and 
aligned using BLASTX with ClustalW 1.7 programs made 
available by Baylor College of Medicine. 
 
3.2. Cell Culture  
ECV304 cells (16) were cloned to obtain a 
monoclonal population (17) and maintained by serial 
passage in M199 supplemented with 10% fetal bovine 
serum (FBS). Human umbilical vein endothelial cells 
(HUVEC) were from American Type Culture Collection 
and cultured in medium M199 containing 10% fetal calf 
serum, endothelial cell growth supplement (150 µg/ml), and 
heparin (5 units/ml) on gelatin-coated dishes. Human 
dermal microvascular cells (HMEC-1) were obtained from 
CDC (Atlanta) and grown in MCDB131 containing 
epidermal growth factor (10 ng/ml), hydrocortisone (1 
µg/ml) and 10% FBS. Nuclear and cytoplasmic extracts 
were obtained as previously described (18). 
 
3.3. Western blot analysis 
A rabbit polyclonal antibody was generated by 
standard procedures immunizing rabbits with a peptide (N-
SIRPPGGLESPVASLPGPAEP-C) contained within the C-
terminus (amino acids 1506-1526) of human HD-PTP. This 
epitope is not conserved in other species. While the 
preimmune serum does not recognize any band, the 
antibody against the peptide recognizes a protein band of 
185 kDa which is consistent with the predicted size of 
human HD-PTP. IgGs against HD-PTP were purified on a 
protein A-Sepharose column. For Western blot, cell extracts 
(75 µg/lane) were resolved by 8% SDS-polyacrylamide gel 
electrophoresis, transferred to nitrocellulose sheets at 
150 mA for 16 h, and probed with anti-HD-PTP IgGs 
(10 µg/ml). PPARgamma and actin antibodies were from 
Santa Cruz (Tebu-bio). Secondary antibodies were labelled 
with horseradish peroxidase (Pierce). The SuperSignal 
chemiluminescence kit (Pierce) was used to detect 
immunoreactive proteins.  
 
3.4. Purification of RNA, Northern blot and RT-PCR 
Cells were rinsed with phosphate-buffered saline 
and lysed in 4 M guanidinium isothiocyanate. RNA was 
purified as described (19). RNA was electrophoresed on a 
1% agarose gel containing 2.2 M formaldehyde, capillary-
blotted onto nylon membranes, and UV-cross-linked. HD-
PTP and glyceraldehyde-3-phosphate dehydrogenase  
(GAPDH) cDNAs were labelled with a random primer 
labelling kit (Ambion Inc.). Filters were hybridized in 
0.5 M sodium phosphate (pH 7.2) containing 7% SDS, 
1 mM EDTA, and 20% formamide at 65 °C for 20 h and 
extensively washed at high stringency. mRNAs were 
visualized by autoradiography. For RT-PCR, 1 µg of RNA 
was reverse transcribed and PCR amplification was carried 
out using 1/50 of the final RT reaction. Each amplification 
cycle consisted of  30 sec at 95°C, 30 sec at 52°C and 1 
min at 72°C using 30 pmol of each primer. The reaction 
was stopped after 30 cycles. One fifth of the reaction mix 
was separated on a 1% agarose gel. The sequences of the 
HD-PTP primers are the following: sense 5’-
GCTGCAGCAGCTACGGGAGTGG-3’ and antisense 5’-
CTCCTTTTACAGGCTGAAGAGTGTC-3’. 
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Figure 1. Modulation of HD-PTP mRNA by Tat. ECV 
cells were exposed to 100 ng/ml Tat for 4 and 24 h. Total 
RNA (10 µg/lane) was analyzed by Northern blotting as 
described. The blot was rehybridized to GAPDH to verify 
equal amounts of RNA loading among the lanes.  
 
 
 
Figure 2. Expression and localization of HD-PTP in human 
endothelial cells. A, western blot was performed on cell 
extracts (75 µg) from ECV cells, HMEC-1 and HUVEC 
using immunopurified IgGs against HD-PTP. B, cell 
fractionation was performed on ECV cells by standard 
protocols. Unfractionated, cytosolic and nuclear extracts 
were analyzed by western blot. PPARgamma and actin 
were utilized as nuclear and cytosolic markers, 
respectively.  
 
 
 
Figure 3. Expression of HD-PTP in ECV cells in response 
to Tat. ECV cells were exposed to 100 ng/ml Tat for 24 and 
48 h. Western blot was performed on 75 µg of cell extracts. 
Actin was used to show that equal amounts of proteins 
were loaded per lane.  
4. RESULTS 
 
4.1. Modulation of HD-PTP RNA by Tat 
By RNA fingerprinting on ECV cells exposed to 
Tat, we obtained several differentially expressed cDNA 
fragments. Sequence analysis and sequence homology 
search (NCBI-Genbank) showed that one clone up-
regulated by Tat encoded for the C-terminal region of HD-
PTP (data not shown), a tyrosine phosphatase located on 
human chromosome 3p21.3 (5). Sequence comparison also 
showed a 70% identity at the nucleotide level to rat PTP-
TD14 (8).   
 
The up-regulation of HD-PTP by Tat detected by 
RNA fingerprinting was confirmed by Northern blot 
analysis in ECV cells exposed to Tat (100 ng/ml). Tat 
increased HD-PTP mRNA with a maximal stimulation 
observed after 4 h (3.0 fold induction) and maintained up to 
24 h (3.5 fold induction) (Figure 1).  
 
4.2. Expression of HD-PTP in endothelial cells. 
A rabbit polyclonal antibody against HD-PTP 
was generated against a hydrophilic C-terminal epitope of 
the human HD-PTP protein. The antibody specifically 
recognized a ~185 kDa protein which corresponds to the 
predicted molecular mass of HD-PTP. Using our antibody, 
ECV, human dermal microvascular endothelial cells 
(HMEC-1) and HUVEC were tested for the total amount of 
HD-PTP by western blot analysis. Figure 2A shows that 
HD-PTP was expressed to a similar extent in the three 
endothelial cell types tested. We also evaluated the 
subcellular localization of HD-PTP in ECV cells after cell 
fractionation. HD-PTP is a cytosolic protein (Figure 2B). 
Similar results were obtained in other cell types, including 
HUVEC and carcinoma cell lines like HeLa and KB (data 
not shown). 
 
4.3. Modulation of HD-PTP in response to Tat and 
angiogenic growth factors 
In spite of the up-regulation of HD-PTP mRNA 
levels in response to Tat, we did not detect any increase of 
HD-PTP protein by western analysis in ECV cells treated 
with Tat (100 ng/ml) (Figure 3), suggesting a possible 
regulation at the post-transcriptional level. 
 
Since Tat binds the VEGF-R2 thus inducing 
angiogenesis, we evaluated whether HD-PTP could be 
modulated also by VEGF. RNA was extracted from ECV 
cells treated  with VEGF (100 ng/ml) for 4, 12 and 24 h. 
Figure 4 A shows that VEGF up-regulated HD-PTP mRNA 
as detected by RT-PCR. However, we did not detect any 
modulation of  HD-PTP at the protein level after 24 and 48 
h incubation in the presence of VEGF (100 ng/ml) (Figure 
4B).  
 
We also exposed ECV cells to FGF-2 (100 
ng/ml) for 4, 12 and 24 h. By RT-PCR we show that no 
modulation of HD-PTP occurs at the mRNA level (fig. 
5A). However, we detected a marked reduction (3 fold) of 
HD-PTP in ECV cells treated with FGF-2 for 24 and 48 h  
(Figure 5B) as detected by western blot.  
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Figure 4. Expression of HD-PTP in ECV cells in response 
to VEGF.A,  ECV cells were exposed to 100 ng/ml VEGF 
for 4, 12 and 24 h. RT-PCR was performed using specific 
primers for HD-PTP. GAPDH was utilized to show that 
equal amounts of RNA had been reverse-transcribed. B, 
ECV cells were exposed to 100 ng/ml VEGF for 24 and 
48 h and western blot was performed as above. Actin was 
used to show that equal amounts of proteins were loaded 
per lane. 
 
 
 
Figure 5. Expression of HD-PTP in ECV cells in response 
to FGF-2.A, ECV cells were exposed to 100 ng/ml FGF for 
4, 12 and 24 h. RT-PCR was performed using specific 
primers for HD-PTP. GAPDH was utilized to show that 
equal amounts of RNA had been reverse-transcribed.B, 
ECV cells were exposed to 100 ng/ml FGF-2 for 24 and 
48 h. Western blot was performed on 75 µg of cell extracts. 
Actin was used to show that equal amounts of proteins 
were loaded per lane.  
 
 
 
Figure 6. Involvement of the proteasome in HD-PTP 
down-regulation by FGF-2. A, ECV cells were exposed to 
FGF-2 (100 ng/ml) and different concentrations of MG132 
(1, 5 and 10 µM). Western blot was performed on 75 µg of 
cell extracts. B, ECV cells were exposed to FGF-2 (100 
ng/ml) and MG132 (5 µM) for different times. Western blot 
was performed on 75 µg of cell extracts. In A and B, actin 
was used to show that equal amounts of proteins were 
loaded per lane. 
4.4. Inhibition of HD-PTP down-regulation by MG132 
We evaluated the down-regulation of HD-PTP by 
FGF-2 in more detail. An important pathway to degrade 
cytoplasmic proteins is via the proteasome (20). The 
proteasome inhibitor MG132 has been widely used to turn 
off the proteasome (21). We first exposed ECV cells to 
FGF-2 (100 ng/ml) in the presence of different 
concentrations of MG132.  We found that HD-PTP down-
regulation after exposure to FGF-2 was prevented by co-
incubating FGF-2 with MG132 (Figure 6A). The effect was 
detected with 1 µM MG132 being maximal at 10 µM.  We 
then performed a time course experiment using 5 µM 
MG132 which was added for 4, 8 and 12 h. As shown in 
Figure 6B, HD-PTP was upregulated within 8 h from the 
exposure to MG132. Similar results were obtained with 
another proteasome inhibitor, i.e. epoxomicin (data not 
shown). 
 
On the contrary, the protein levels of HD-PTP 
remained unchanged after treatment with Tat in the 
presence of MG132 (data not shown), suggesting that a 
different pathway is used by Tat to modulate HD-PTP. 
 
5. DISCUSSION 
 
Tyrosine phosphorylation is a fundamental 
regulatory mechanism in eukaryote physiology (22). PTPs 
and PTKs regulate the reversible phosphorylation of 
tyrosine residues in proteins, thereby controlling cell 
growth and differentiation, gene transcription and 
metabolism (22). Indeed, interference with the delicate 
balance between PTKs and PTPs is involved in the 
development of human diseases such as autoimmunity, 
diabetes and cancer (23). While the role of PTKs has been 
largely addressed, recent findings have led to the emerging 
recognition that PTPs play specific and active, even 
dominant, roles in setting the levels of tyrosine 
phosphorylation in cells (22,24). One hundred and seven 
PTP genes have been found in the human genome (25). Of 
these, 85 are thought to be catalytically active and there is a 
growing experimental evidence that PTPs tend to be very 
specific (24). 
 
For the first time, we report the initial 
characterization of a recently isolated putative PTP, HD-
PTP, and its regulation both at the RNA and protein level in 
endothelial cells exposed to angiogenic factors. Tat, a 
transactivator of both viral and host gene, up-regulates HD-
PTP mRNA, while no modulation is detected at the protein 
level.  In ECV cells, we also show that FGF-2 markedly 
down-modulates HD-PTP protein, whereas VEGF does not. 
The down-regulation of HD-PTP in FGF-2 treated cells is 
intriguing since an interesting feature of HD-PTP is the 
presence of a PEST motif located at the C-terminus.  PEST 
sequences are found in many short-lived eukaryotic 
proteins and play a relevant role in their degradation (26). 
In particular, many PEST-containing proteins are degraded 
through the proteasome (27). Accordingly, the proteasome 
inhibitor MG132 prevents FGF-2 induced down-regulation 
of HD-PTP, thus suggesting that HD-PTP levels are post-
transcriptionally regulated via the proteasome. Since the 
proteasome represents an important mechanism to degrade 
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many proteins implicated in signal transduction (26), it is 
worth noting that HD-PTP is the first described PEST-
containing tyrosine phosphatase regulated by the 
proteasome.  
 
The up-regulation of HD-PTP mRNA by Tat 
does not result in an increase of its protein levels. On the 
basis of the results obtained with FGF-2, we anticipated 
that the proteasome could be involved as well.  However, 
MG132 does not modulate the levels of HD-PTP in ECV 
cells treated with Tat.  It is possible that proteases other that 
the proteasome are involved in the regulation of HD-PTP 
and more studies are required to test this possibility.  Since 
Tat binds the VEGF-R2, it is noteworthy that both Tat and 
VEGF do not affect the total amount of HD-PTP protein, 
while they both modulate its mRNA.  The different effect 
on HD-PTP elicited by FGF-2 and VEGF is intriguing.  It 
should be recalled that FGF-2 and VEGF activate the 
angiogenic program in endothelial cells through the 
activation of different pathways (28). FGF receptor-1 
activation, but not VEGF-R1 or VEGF-R2,  stimulates Crk 
kinase and Grb2/Sos complex which induce the activation 
of Ras (29). Interestingly, the rat homologue of HD-PTP, 
denominated PTP-TD14, suppresses Ha-Ras-mediated 
transformation by ~3 fold in NIH-3T3 cells (8). Taken 
together, these data suggest that HD-PTP negatively 
controls Ras pathway. Consequently, FGF-2 induced down-
regulation of HD-PTP might participate in promoting the 
activation of Ras, which instead is not induced by Tat and 
VEGF. Since Ras is central in a variety of cellular 
functions such as proliferation and migration as well as 
cancer progression, HD-PTP could contribute to their 
regulation. Further studies are necessary to address HD-
PTP role as well as its enzymatic activity and its regulation 
in endothelial cells. 
 
The data presented in this study suggest that HD-
PTP might participate in modulating endothelial response 
to angiogenic factors and, therefore, play a role in 
regulating the complex events leading to the formation of 
new vessels. 
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